Last updated: 23 December 2018 at 12:12pm EST

Lifesciences Iii, L.P.Claru... Net Worth




The estimated Net Worth of Lifesciences Iii, L.P.Claru... is at least $3.56 Milion dollars as of 28 September 2018. Lifesciences Claru owns over 453,395 units of Entasis Therapeutics Inc stock worth over $3,555,257 and over the last 6 years Lifesciences sold ETTX stock worth over $0.

Lifesciences Claru ETTX stock SEC Form 4 insiders trading

Lifesciences has made over 1 trades of the Entasis Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Lifesciences bought 453,395 units of ETTX stock worth $6,800,925 on 28 September 2018.

The largest trade Lifesciences's ever made was buying 453,395 units of Entasis Therapeutics Inc stock on 28 September 2018 worth over $6,800,925. On average, Lifesciences trades about 453,395 units every 0 days since 2018. As of 28 September 2018 Lifesciences still owns at least 1,623,405 units of Entasis Therapeutics Inc stock.

You can see the complete history of Lifesciences Claru stock trades at the bottom of the page.



Insiders trading at Entasis Therapeutics Inc

Over the last 6 years, insiders at Entasis Therapeutics Inc have traded over $348,925 worth of Entasis Therapeutics Inc stock and bought 50,891,639 units worth $170,673,776 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Inc.Innoviva Strategic Oppo... oraz Holdings A/S Novo. On average, Entasis Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $4,855,580. The most recent stock trade was executed by Inc.Innoviva Strategic Oppo... on 8 July 2022, trading 19,270,476 units of ETTX stock currently worth $42,395,047.



What does Entasis Therapeutics Inc do?

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).



What does Entasis Therapeutics Inc's logo look like?

Entasis Therapeutics Holdings Inc logo

Complete history of Lifesciences Claru stock trades at Entasis Therapeutics Inc

Data
#
Firma
Osoba
Trans.
Transakcja
Ilość akcji Cena za akcję Łączna cena Ilość akcji po Źródło
28 Sep 2018 Lifesciences Iii, L.P.Claru...
Kupować 453,395 $15.00 $6,800,925
28 Sep 2018
1,623,405


Entasis Therapeutics Inc executives and stock owners

Entasis Therapeutics Inc executives and other stock owners filed with the SEC include: